In summary, translating the pathophysiological mechanisms of acromegaly into implant outcomes requires structured evidence from prospective studies, including (i) standardized assessment of disease activity (GH, IGF-1), bone remodeling markers, and microarchitectural parameters; (ii) careful evaluation and documentation of comorbidities and their management; (iii) objective integration outcomes (primary/secondary stability, BIC from imaging or indirect measures, and marginal bone loss); and (iv) long-term clinical follow-up. The gene discussed is IGF1; the disease is acromegaly.